Not much happening in the sector or markets outside of the ongoing issues in the Middle East. We will likely get a press conference today that blames Iran for the.
So I was thinking that any response to the attacks on Saudi Arabia would happen sooner rather than later but I am no longer convinced that remains the case. Clearly.
It is looking like a macro week, although this could resolve itself fairly quickly. The attacks on the ARAMCO production facility is likely to have long term effects on oil.
San Diego based Turning Point Therapeutics is an oncology focused biotech that completed a successful IPO in April this year, raising about $190M with pricing at $18/sh. As the stock.
Surprise. The sector is weak. I am a little surprised that we are not see a faster sell off as clearly there is no momentum and we have broken support. .
I have class about to begin but I want to put out a quick note on the news. GBT announced that the FDA has accepted the NDA for voxelotor with.
The sector is in an odd spot. It seems to be right under a major support but has not quite broken down. I suspect we cannot remain at these levels.
I will keep this short and sweet as there is little news to talk about. On the positive side, the sector seems to be doing better and while I would.
Aug 27, 2019 by Jason Chew Zogenix announced yesterday that it is acquiring privately held Modis Therapeutics. It gains access to the late stage substrate enhancement therapy, MT1621, for the.
Aug 23, by Jason Chew Arvinas is one of the newer names I’ve been covering. The company is developing a new class of drugs with a new modality known as.
Broadly speaking the sector and market are doing well. Sentiment has been pretty negative and there were some macro concerns. This seems to be easing a bit, so a rally.
Aug 19, 2019 by Jason Chew Zogenix ran into some unwelcome surprise this April when FDA kicked back its ZX008 (Fintepla) NDA with a Refuse to File letter. The two deficiencies cited.